Tue. Nov 17th, 2026
Stock image obtained from Pexels

Biological sex and genetic risk factors may influence how neurological conditions develop and respond to treatment, according to new research findings set to be presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.

The findings highlight differences in Alzheimer’s disease (AD) and fibromyalgia, suggesting that treatment approaches may need to account for individual biological and genetic profiles. Researchers examined the effects of menopause hormone therapy, changes in brain circuits, immune responses and chronic gut inflammation to understand how these conditions affect males and females differently.

Genetic Risk May Influence Response to Menopause Hormone Therapy

One study found that people with a genetic risk for Alzheimer’s disease responded differently to menopause hormone therapy (MHT) compared with those without the same risk.

The researchers also observed that responses varied depending on the hormonal formulation used in the therapy. The findings suggest that both genetic risk and the specific formulation of MHT may need to be considered when evaluating treatment options.

The research was presented by Mateja Perović of the University of Toronto.

Another study, led by Stephanie M. Perez of the University of Texas Health Science Center at San Antonio, examined menopausal rodents with a genetic risk for Alzheimer’s disease.

Researchers found that brain circuits associated with memory became particularly vulnerable in these animals. The findings support the possibility that menopause may represent a period of increased vulnerability for women who are already at risk of developing Alzheimer’s disease.

Female Mice Show Greater Immune Activation in Fibromyalgia Model

Researchers also investigated sex-based differences in fibromyalgia, a chronic condition characterised by persistent pain and fatigue that affects an estimated 2-4% of the global population.

A study led by Yasmin Sahlloul of the University of Cincinnati found that female mice in a fibromyalgia model remained sensitive to touch and displayed greater immune activation than male mice.

The findings suggest that biological sex may influence pain sensitivity and immune responses in fibromyalgia. Researchers indicated that these differences could have implications for developing treatment approaches tailored to the needs of different patients.

Gut Inflammation May Affect Alzheimer’s Pathology Differently

A separate study examined the relationship between chronic gut inflammation and brain function in a mouse model of Alzheimer’s disease.

Led by Nurcan Kilic of the University of North Dakota, the research found that prolonged gut inflammation affected brain function and Alzheimer’s-related pathology differently in male and female mice.

The findings add to growing research into the connection between inflammation, the gut and neurological health, while highlighting the importance of examining sex-based differences in disease progression.

Researchers Highlight Importance of Precision-Based Treatment

The four studies collectively point to the role of biological sex and genetic factors in shaping neurological health and treatment responses.

Liisa Galea, PhD, Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health and moderator of the press conference, said: “These four studies illustrate the fascinating discoveries that can be made when focusing on female-specific biology or possible sex differences in AD-related symptoms and risk factors,”

She added: “The research presented at Neuroscience 2026 helps us pinpoint the specific differences that may help us develop more targeted treatment using precision approaches, even for some of our most complex brain disorders.”

The findings will be presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience. They highlight how research into sex-specific biology could contribute to more personalised approaches to treating conditions such as Alzheimer’s disease and fibromyalgia.

Alzheimer’s disease is a progressive neurological disorder associated with memory loss and declining brain function. It remains incurable and affects an estimated 35-40 million people worldwide, according to the World Health Organization.


Read More :

Molecular Testing Advances Could Improve STI Treatment and Endometrial Cancer Risk Assessment

NPPA Orders Strict Monitoring of Revised Prices for 137 Anti-Cancer Drugs

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.